ESTRELLA IMMUNOPHARMA, INC. Income (Loss) Attributable to Parent, before Tax
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Income (Loss) Attributable to Parent, before Tax of -$469.53 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2024-05-15
- ESTRELLA IMMUNOPHARMA, INC. income (loss) attributable to parent, before tax for the quarter ending 2024-03-31 was -$469.53K.
- ESTRELLA IMMUNOPHARMA, INC. income (loss) attributable to parent, before tax for the quarter ending 2023-12-31 was -$1.02M.
- ESTRELLA IMMUNOPHARMA, INC. income (loss) attributable to parent, before tax for the quarter ending 2023-03-31 was -$2.74M.
- ESTRELLA IMMUNOPHARMA, INC. income (loss) attributable to parent, before tax for the quarter ending 2022-12-31 was -$2.76M.
| Period end | Income (Loss) Attributable to Parent, before Tax 3 month | Income (Loss) Attributable to Parent, before Tax 6 month | Income (Loss) Attributable to Parent, before Tax 9 month |
|---|---|---|---|
| 2024-03-31 | -$469.53K 10-Q · filed 2024-05-15 | -$1.49M derived: sum of 2 quarters · filed 2024-05-15 | -$3.36M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$1.02M 10-Q · filed 2024-02-14 | -$2.89M 10-Q · filed 2024-02-14 | |
| 2023-03-31 | -$2.74M 10-Q · filed 2024-05-15 | -$5.50M derived: sum of 2 quarters · filed 2024-05-15 | -$8.38M 10-Q · filed 2024-05-15 |
| 2022-12-31 | -$2.76M 10-Q · filed 2024-02-14 | -$5.64M 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |